Opinion on Oncology in Finland

Select information type

Refine your search

search
Search tips

by industry

Published within

« | 1 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Eli Lilly: Gemzar gets Finnish approval

Regulatory officials in Finland have approved an expanded indication for Eli Lilly's [LLY] Gemzar (gemcitabine) in combination with paclitaxel for advanced breast cancer. Further EU and, most importantly, US approval should follow soon, providing Gemzar with a large range of indications and blockbuster status by the end of 2003.

Published By Datamonitor
02 Jul 2003
CommentWire
CommentWire

Ark Therapeutics: targeting a new era for oncology?

Ark Therapeutics has announced that its novel gene-based targeting technology Scavidin can halt tumor progression while preventing chemotherapy side effects. Although clinical trials are urgently required to confirm Scavidin's efficacy, this leading edge technology could spell the end for unpleasant toxicities associated with chemotherapy and radiation, particularly for elderly patients.

Published By Datamonitor
22 Feb 2006

« | 1 | » »|

No help is available.